Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain

INTRODUCTION: Many patients at very high risk of cardiovascular (CV) events would benefit from lipid-lowering therapies (LLT) intensification to decrease their risk. This study aimed to identify the real-world secondary prevention patients potentially eligible for proprotein convertase subtilisin–ke...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosin-Sales, Juan, Sidelnikov, Eduard, Villamayor, Santiago, Fernández, Miriam, Merino-Montero, Sandra, Zamora, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220136/
https://www.ncbi.nlm.nih.gov/pubmed/36525203
http://dx.doi.org/10.1007/s12325-022-02384-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220136/
https://www.ncbi.nlm.nih.gov/pubmed/36525203
http://dx.doi.org/10.1007/s12325-022-02384-y

Ejemplares similares